MYL Mylan NV

21.000.00 (+0.00%)
Close: September 20, 2019

Quote

Previous Close
$21.00
Day Range
$20.60-$21.39
52 Week Range
$16.63-$39.59
Volume
9,182,651
Avg Volume
5,426,944
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$10.83B
Enterprise Value (EV)
$24.22B
PE Ratio
350.00
EV/EBITDA
7.22
Price/Sales
0.95
Price/Book
0.89
PEG Ratio
-

Financials

Revenue
$11.43B
Gross Profit
$4.34B
EBITDA
$3.35B
EPS, ttm
$0.06
Profit Margin
3.08%
Revenue/Employee
$326.51K
Next Earnings Date
11/11/2019 (50 days)
Debt to Equity
114%
Debt
$13.86B
Cash
$480.60M
Net Debt
$13.38B

Performance

Beta
1.39
200 Day Moving Avg
$24.14
50 Day Moving Avg
$19.60
52 Week Change
-46.14%
YTD Change
-24.79%
1 Month Change
10.01%
3 Month Change
14.63%
6 Month Change
-28.21%
1 Year Change
-46.14%
2 Year Change
-24.40%
5 Year Change
-41.31%

Share Count

Shares Outstanding
515.9M
Float
512.8M
Restricted Shares
3.0M
Restricted Shares, %
0.59%

Mylan NV Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Generic

CEO: Heather M. Bresch

Website: http://mylan.co.uk

Description: Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Employees: 35,000